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ABSTRACT

A novel computational method and generation of mutant

butyrylcholinesterase for cocaine hydrolysis is provided. The
method includes molecular modeling a possible BChE
mutant and conducting molecular dynamics simulations and
hybrid quantum mechanical/molecular mechanical calcula
tions thereby providing a screening method of possible BChE
mutants by predicting Which mutant Will lead to a more stable
transition state for a rate determining step. Site-directed

mutagenesis, protein expression, and protein activity is con
ducted for mutants determined computationally as being
good candidates for possible BChE mutants, i.e., ones pre

dicted to have higher catalytic e?iciency as compared With
Wild-type BChE. In addition, mutants A199S/A328W/

Y332G, A199S/F227A/A328W/Y332G, A199S/S287G/

Gao, et al.; Modeling effects of oxyanion hole on the ester hydrolyses

A328W/Y332G,

catalyzed by human cholinesterases; Phys. Chem. B; 2005; 109; pp.

and

23070-23076.

enhanced catalytic ef?ciency for (—)-cocaine compared With
Wild-type BChE.

Gao, et al; Computational design of a human butyrylcholinesterase
mutant for accelerating cocaine hydrolysis based on the

A199S/F227A/S287G/A328W/Y332G,

A199S/F227A/S287G/A328W/E441D

transitionistate simulation; Angew. Chem. Int. Ed.; 2006; 45; pp.
653-657.
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HIGH-ACTIVITY MUTANTS OF
BUTYRYLCHOLINESTERASE FOR
COCAINE HYDROLYSIS AND METHOD OF
GENERATING THE SAME

-continued
H3C

\N+/H
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This application is a division of and claims bene?t to US.

patent application Ser. No. 11/243,111, now allowed, ?led
OCH3

Oct. 4, 2005 now US. Pat. No. 7,438,904. The contents of

+

which are incorporated herein by reference in their entirety.
OH

H3C

GOVERNMENT SUPPORT CLAUSE
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H

Subject matter described herein was made with govem
ment support under Grant Number R01DA013930 awarded

O
BChE

by the National Institute on Drug Abuse (NIDA) of the
National Institutes of Health (NIH). The government has
certain rights in the described subject matter.

+

H20

—>

OCH3
20

O

/

O=C

FIELD OF THE INVENTION

The present invention relates to butyrylcholinesterase vari

25

(+)—cocaine

ant polypeptides, and in particular, butyrylcholinesterase
mutants having amino acid substitutions.

H3C

/H

O§C/OH

BACKGROUND OF THE INVENTION
30

O

Cocaine abuse is a major medical and public health prob

+

lem that continues to defy treatment. The disastrous medical
and social consequences of cocaine addiction, such as violent

crime, loss in individual productivity, illness and death, have

OCH3
35

made the development of an effective pharmacological treat
ment a high priority. However, cocaine mediates its reinforc

ing and toxic effects by blocking neurotransmitter reuptake
and the classical pharmacodynamic approach has failed to
yield small-molecule receptor antagonists due to the di?icul

40

ties inherent in blocking a blocker. An alternative to receptor

based approaches is to interfere with the delivery of cocaine
to its receptors and accelerate its metabolism in the body.
The dominant pathway for cocaine metabolism in primates

OH

Scheme 1. Schematic representation of BChE-catalyzed
hydrolysis at the benzoyl ester group.
Only 5% of the cocaine is deactivated through oxidation by
the liver microsomal cytochrome P450 system. Cocaine

hydrolysis at benzoyl ester group yields ecgonine methyl
45

is butyrylcholinesterase (BChE)-catalyzed hydrolysis at the
benzoyl ester group (Scheme 1).

ester, whereas the oxidation produces norcocaine. The
metabolite ecgonine methyl ester is a biologically inactive
metabolite, whereas the metabolite norcocaine is hepatotoxic
and a local anesthetic. BChE is synthesized in the liver and

widely distributed in the body, including plasma, brain, and
50

lung. Extensive experimental studies in animals and humans
demonstrate that enhancement of BChE activity by adminis
tration of exogenous enzyme substantially decreases cocaine
half-life.
Enhancement of cocaine metabolism by administration of
BChE has been recognized to be a promising pharmacoki

netic approach for treatment of cocaine abuse and depen

BChE

ocn3

+

H20

dence. However, the catalytic activity of this plasma enzyme
is three orders-of-magnitude lower against the naturally
occurring (—)-cocaine than that against the biologically inac

—>

60

tive (+)-cocaine enantiomer. (+)-cocaine can be cleared from
plasma in seconds and prior to partitioning into the central
nervous system (CNS), whereas (—)-cocaine has a plasma

half-life of approximately 45-90 minutes, long enough for
manifestation of the CNS effects which peak in minutes.

Hence, BChE mutants with high activity against (—)-cocaine
65

are highly desired for use in humans. Although some BChE

mutants with increased catalytic activity over wild-type
BChE have previously been generated, there exists a need for

US 7,731,957 B1
3

4

mutant BChE with even higher catalytic activity. Thus, prior
mutants provide limited enhancement in catalytic activity

previously published theoretical model of this enzyme and to
the structure of acetylcholinesterase.
The main difference between the experimentally deter

over wild-type BChE.

Previous studies such as (a) Masson, P.; Legrand, P.; Bar

mined BChE structure and its model was found at the acyl

tels, C. F.; Froment, M-T.; Schopfer, L. M.; Lockridge, 0.
Biochemistry 1997, 36, 2266 (b) Masson, P.; Xie, W., Fro
ment, M-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lock
ridge, O. Biochim. Biophys. Acta 1999, 1433, 281, (c) Xie,
W.; Altamirano, C. V.; Bartels, C. F.; Speirs, R. J.; Cashman,
J. R.; Lockridge, 0. Mol. Pharmacol. 1999, 55, 83, (d) Duy

binding pocket (acyl loop) that is signi?cantly bigger than
expected. It is unclear whether the structural difference at the

acyl binding pocket signi?cantly affect BChE binding with
(—)-cocaine and (+)-cocaine. Although previous MD simula
tions of cocaine binding with wild-type BChE and the reac
tion coordinate calculations point to some amino acid resi
dues that might need to be mutated for the purpose of

sen, E. G.; Bartels, C. F.; Lockridge, O. J. Pharmacol. Exp.

Ther. 2002, 302, 751, (e) Nachon, F.; Nicolet,Y.; Vlguie, N.;
Masson, P.; Fontecilla-Camps, J. C.; Lockridge, 0. Eur. J.
Biochem. 2002, 269, 630, (f) Zhan, C.-G.; Landry, D. W. J.
Phys. Chem. A 2001, 105, 1296; Berkman, C. E.; Underiner,
G. E.; Cashman, J. R. Biochem. Pharmcol. 1997, 54, 1261;

(g) Sun, H.; Yazal, J. E.; Lockridge, O.; Schopfer, L. M.;
Brimijoin, S.; Pang,Y.-P. J. Biol. Chem. 2001, 276, 9330, (h)
Sun, H.; Shen, M. L.; Pang,Y. P.; Lockridge, O.; Brimijoin, S.
J. Pharmacol. Exp. Ther. 2002, 302, 710, Sun, H.; Pang,Y.
P.; Lockridge, O.; Brimijoin, S. Mol. Pharmacol. 2002, 62,
220 (hereinafter “Sun et al”); and (j) Zhan, C.-G.; Zheng, F.;

improving the catalytic activity for (—)-cocaine hydrolysis, it
remained unknown which exact amino acid mutations will

result in a BChE with a higher catalytic activity for (—)
cocaine.
Computational studies of wild-type BChE and cocaine
from Sun, et al, based on a “homology model,” suggest that
20

cocaine is the rotation of the cocaine in the active site of

Landry, D. W. J. Am. Chem. Soc. 2003, 125, 2462 (hereinafter

“Zhan et al”), herein all incorporated by reference, suggested
that, for both (—)-cocaine and (+)-cocaine, the BChE-sub
strate binding involves two different types of complexes:

the rate-determining step for BChE-catalyzed hydrolysis of

25

BChE. By decreasing the hindrance of the rotation, the rate of
the hydrolysis may be enhanced. Sun, et al describes creating
an A328W/Y332A BChE mutant by: (1) replacing Tyr332
with Ala, “to reduce the steric hindrance and the 313-313 interac

non-prereactive and prereactive BChE-substrate complexes.

tion that impede rotation,” and (2) replacing Ala328 with Trp

Whereas the non-prereactive BChE-cocaine complexes were
?rst reported by Sun et al, Zhan et al were the ?rst reporting
the prereactive BChE-cocaine complexes and reaction coor
dinate calculations, disclosed in Zhan et al.
It was demonstrated that (—)/(+)-cocaine ?rst slides down
the substrate-binding gorge to bind to W82 and stands verti
cally in the gorge between D70 and W82 (non-prereactive
complex) and then rotates to a position in the catalytic site
within a favorable distance for nucleophilic attack and

“to provide a cation-n interaction to restore substrate a?inity
lost in disabling the 313-313 interaction.”
Sun et al studied the A328W/Y332A BChE mutant using
enzyme assays and kinetics. In vitro studies were conducted
using human plasma and in vivo studies were conducted
using male Sprague-Dawley rats. The mutant was found to
have enhanced catalytic properties. The mutant was further

30

35

studied using molecular modeling. The three dimensional

hydrolysis by $198 (prereactive complex). In the prereactive

(3D) structure of A328W/Y332A was generated from the

complex, cocaine lies horizontally at the bottom of the gorge.
The main structural difference between the BChE-(—)-co

computationally generated 3D model of wild-type BChE and
changing the relevant residues using commercially available

caine complexes and the corresponding BChE-(+)-cocaine

40

complexes exists in the relative position of the cocaine methyl
ester group. Reaction coordinate calculations revealed that

the rate-determining step of BChE-catalyzed hydrolysis of
(+)-cocaine is the chemical reaction process, whereas for

(—)-cocaine the change from the non-prereactive complex to
the prereactive complex is rate determining. A further analy

45

(molecular docking and molecular dynamics simulation)
50

catalytic activity for (—)-cocaine.
Previous molecular dynamics (MD) simulations of prere
active BChE-cocaine binding were limited to wild-type

BChE. Even for the non-prereactive BChE-cocaine complex,
only one mutant (A328W/Y332A) BChE binding with (—)
cocaine was simulated and its catalytic activity for (—)-co

55

caine was reported by Sun et al. No MD simulation was

performed on any prereactive enzyme-substrate complex for
(—)- or (+)-cocaine binding with a mutant BChE. In addition,
all previous computational studies of Sun et al and Zhan et al

60

of BChE interacting with cocaine were performed based on a

X-ray crystal structure was not available for BChE, as taught

by Nicolet,Y.; Lockridge, O.; Masson, P.; Fontecilla-Camps,
of BChE. As expected, the structure of BChE is similar to a

used by other researchers are based on an empirical force ?eld
which cannot be used to perform any necessary reaction
coordinate calculation for the detailed understanding of the

complicated catalytic reaction process. As it is well-known, it
is particularly challenging to model and simulate the detailed
reaction pathway and predict the kinetics of such an enzy
matic reaction.
U.S. Patent Application Publication Nos. 2004/0121970;
2004/0120939; and 2003/0153062, describe 20+BChE
mutants, or “variants,” from human and other animals, each
having from one to six amino acid alterations and increased

cocaine hydrolysis activity. For example, mutants include
F227A/A328W; F227A/S287G/A328W; A119S/S287G/
A328W; A328W/Y332M/S287G/F227A, A199S/F227A/S/

homology model of BChE when three-dimensional (3D)
J. C.; Nachon, F. J. Biol. Chem. 2003, 278, 41141 (hereinafter
“Nicolet et al”), recently reported 3D X-ray crystal structures

modeling studies were consistent with enzyme assays and
kinetic data.

It should be noted that all prior computational techniques

sis of the structural changes from the non-prereactive com

plex to the prereactive complex reveals speci?c amino acid
residues hindering the structural changes, providing initial
clues for the rational design of BChE mutants with improved

software. Cocaine was docked to the catalytic gorge of the

mutant BChE using other commercially available software.
The cocaine-enzyme complex was re?ned by molecular
dynamic simulation. The data generated by the molecular

65

287G/A328W and A119S/F227A/S287G/A328W/Y332M.

The mutants have varying increases in catalytic activity, up to
100-fold increase relative to wild-type BChE.

US 7,731,957 B1
6

5
There exists a need in the art for determining which pro

The experimental tests are conducted on mutants which are

posed mutant BChEs should have ever increasing catalytic
activity and for generating those mutants which should have

predicted to have a high catalytic ef?ciency against (—)-co

enhanced catalytic activity.

mutants against (—)-cocaine. Thus, the present method iden
ti?es or predicts mutants having high catalytic activity for

caine than the wild-type BChE and/or other known BChE

cocaine hydrolysis by performing molecular modeling and

SUMMARY OF THE INVENTION

The present invention includes ?ve novel human BChE

MD simulations on the transition state structures of possible
mutants of BChE. This method is an improvement over tra

mutants that have unexpected increased catalytic ef?ciency
for cocaine hydrolysis. The mutants have various unique
amino acid residue substitutions which provide the surprising

ditional random-search approaches, which, given the com
plex catalytic mechanism of cocaine hydrolysis, makes it
dif?cult to improve the catalytic activity of BChE for cocaine

enhanced catalytic activity. These mutants are (1) a 199S/
A328W/Y332G mutant (SEQ ID NO: 2), which has a

hydrolysis.

approximately 65-fold improved catalytic ef?ciency against

linesterase variant peptide comprising an amino acid
sequence selected from the group consisting of SEQ ID NOS:

The present invention in one form, concerns a butyrylcho

(—)-cocaine; (2) a 199S/F227A/A328W/Y332G mutant
(SEQ ID NO: 8), which has an approximately 148-fold

2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30.

improved catalytic ef?ciency against (—)-cocaine; (3) a 199S/

The present invention in another form thereof concerns a

S287G/A328W/Y332G mutant (SEQ ID NO: 14), which has

nucleic acid molecule comprising a nucleic acid sequence
which encodes a butyrylcholinesterase variant peptide, the
nucleic acid sequence selected from the group consisting of

an approximately 456-fold improved catalytic ef?ciency
against (—)-cocaine; a 199S/F227A/S287G/A328W/Y332G
mutant (SEQ ID NO: 20), which has an approximately 1,003

20

SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27,

fold improved catalytic ef?ciency against (—)-cocaine; and a

and 29.
The present invention in another form thereof concerns a

199S/F227A/S287G/A328W/E441D mutant (SEQ ID NO:

26), which has an approximately 445-fold improved catalytic

ef?ciency against (—)-cocaine.

pharmaceutical composition comprising a butyrylcholinest
25

In addition, the aforementioned mutant amino acid
sequences can be truncated without substantially affecting
the catalytic activity so that amino acid residues 1-67 and
443-574 can be removed without substantially affecting the

catalytic activity of the enzyme. SEQ ID NOS: 4, 10, 16, 22

erase variant polypeptide comprising an amino acid sequence

selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8,
10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30; and a suitable

pharmaceutical carrier.
The present invention in another form thereof concerns a
30

method for treating a cocaine-induced condition comprising

and 28 are the amino acid sequences for residue 68-142

administering to an individual an effective amount of butyryl

corresponding to mutants 1-5, respectively. In addition, with

cholinesterase variant peptide having an amino acid sequence
selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8,

regard to mutants 1-4, it was found that amino acid residues
before 117 and after 438 could be removed without substan

tially changing the activity of the mutant enzymes, resulting
in truncated amino acid sequences having SEQ ID NOS: 6,
12, 18 and 24, respectively. Finally with regard to mutant 5,

10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30, to lower blood
35

cocaine concentration.
The present invention is another form thereof concerns a

method for treating a cocaine induced condition comprising

amino acid residues before 117 and after 441 could be

administering to an individual an effective amount of a phar

removed without substantially changing its activity resulting

maceutical composition comprising a butyrylcholinesterase

in SEQ ID NO: 30.
These aforementioned truncated sequences all of with
similar catalytic activity is based on protein structures.
Further, the present invention is directed to a novel and

unique pharmaceutical composition which comprises a
butyrylcholinesterase variant, namely mutants 1-5, along

40

group consisting ofSEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 18,
20, 22, 24, 26, 28, and 30, and suitable pharmaceutical carrier
of claim 3 to an individual in an effective amount to lower
45

with a suitable pharmaceutical carrier. The pharmaceutical
composition can be administered to an individual in an effec

tive amount to lower the patient’s cocaine blood concentra

blood cocaine concentration.
The present invention in yet another form thereof concerns
a method for generating butyrylcholinesterase mutants. The
method includes generating an initial structure of the transi
tion state structure for the rate-determining step of the

cocaine hydrolysis catalyzed by a possible butyrylcholinest

tion and in particular (—)-cocaine blood concentration.
In addition, the present invention is directed to a novel and

variant having an amino acid sequence selected from the

50

unique method for developing mutants which have enhanced
catalytic ef?ciency. The generation method includes both a

erase mutant. A suf?ciently long time molecular dynamics
simulation is performed on the transition state structure in
water to have a stable molecular dynamics trajectory. The

computational portion and an experimental portion. With

molecular dynamics trajectory is analyzed and the hydrogen

regard to the computational portion, a variety of state of the

bonding energies are estimated between the carboxyl oxygen
of the (—)-cocaine benzyl ester and the oxyanion hole of the
possible butyrylcholinesterase mutant. If the overall hydro
gen binding energy between the carboxyl oxygen of the (—)
cocaine benzyl ester and the possible butyrylcholinesterase
mutant, in the transition state, is stronger than the overall
hydrogen binding energy between the carboxyl oxygen of the

art computational techniques including molecular modeling,
molecular dynamics (MD) simulations and hybrid quantum
mechanical/molecular mechanical (QM/MM) calculations,

55

provide a virtual screening of possible BChE mutants. This
virtual screening predicts which mutation will lead to a more
stable transition state for a rate-determining step compared to

60

(—)-cocaine benzyl ester and the wild-type butyrylcholinest
erase, optionally, hybrid quantum mechanical/molecular
mechanical (QM/MM) geometry optimization is performed

the corresponding separated reactants, i.e., free cocaine and
free enzyme. The more stable the transition state, the lower

the energy barrier, and the higher the catalytic ef?ciency.
Following the computational portion, an experimental test is
portion. The experimental test includes site-directed

to re?ne the molecular dynamics-simulated structure, the
hydrogen binding energies are calculated and the energy bar
rier is evaluated. Finally, the butyrylcholinesterase mutant is

mutagenesis, protein expression, and enzyme activity assay.

generated.

then conducted on the possible mutants of the computation

65

US 7,731,957 B1
8

7

rotation in the BChE active site where none of the aforemen

In various alternative embodiments, the generating an ini
tial structure of the transition state structure is based on reac

tioned residues hinders the (+)-cocaine rotation in the BChE
active site from the non-prereactive complex to the prereac
tive complex in accordance with the present invention.
FIG. 4A depicts the (—)-cocaine rotation in the active site of

tion coordinate calculations for the wild-type butyrylcho
linesterase. The generating butyrylcholinesterase mutant
includes performing site-directed mutagenesis on a nucleic

acid sequence which includes wild-type butyrylcholinest

A328W/Y332A; FIG. 4B depicts the (—)-cocaine rotation in

erase to generate the mutant butyrylcholinesterase nucleic

the active site of A328W/Y332G BChE from the non-preac

acid sequence. Using the mutant butyrylcholinesterase
nucleic acid sequence, the protein encoded by the mutant
nucleic acid sequences is expressed to produce mutant

tive complex to the prereactive complex; and FIG. 4C depicts
the (—)-cocaine rotation in the active site of wild-type BChE.
FIG. 5A is a plot of the key internuclear distances (in A)

butyrylcholinesterase and catalytic activity assay is per

versus the time in the simulated TSl structure for (—)-cocaine

formed on the mutant butyrylcholinesterase.

hydrolysis catalyzed by A328W/Y332A; and FIG. 5B for

The hybrid quantum mechanical/molecular mechanical

geometry optimization may include calculating the hydrogen
binding energies and evaluating the energy barriers only if the
overall hydrogen binding energy between the carboxyl oxy
gen of the (—)-cocaine benzyl ester and the possible butyryl

FIG. 6 is a plot of key internuclear distances (in A) versus
the time in the simulated TSl structure for (—)-cocaine

cholinesterase mutant, in the transition state, is stronger than

BChE.

Al 99S/A328W/Y332G BChE.

hydrolysis catalyzed by Al99S/S287G/A328W/Y332G

known butyrylcholinesterase mutants against (—)-cocaine.
In yet another alternative further embodiment, the method
for generating butyrylcholinesterase mutants further includes

20

DETAILED DESCRIPTION OF THE PREFERRED
EMBODIMENTS

determining the rate-limiting step in the hydrolysis of (—)
cocaine by the possible butyrylcholinesterase mutant by con
ducting molecular dynamics simulations and quantum
mechanical/molecular mechanical calculations relating to the
transition states for other reaction steps between (—)-cocaine

25

by the possible butyrylcholinesterase mutant and calculating
respective energy barriers, thereby establishing which of the
reaction steps is the rate-determining one.
30

The present invention has two major improvements over
the prior art. The ?rst is the presently discovered BChE
mutants, mutant 1, Al99S/A328W/Y332G; mutant 2,
Al99S/F227A/A328W/Y332G; mutant 3, Al99S/S287G/
A328W/Y332G; mutant 4, Al99S/F227A/S287G/A328W/
Y332G; and mutant 5, Al99S/F227A/S287G/A328W/

BRIEF DESCRIPTION OF THE DRAWINGS

E44lD each have a signi?cantly higher catalytic ef?ciency.
The second improvement is concerning the mutant designing

FIG. 1 are plots of distances in the MD simulation (—)
cocaine binding with A328W/Y332G BChE versus the simu

or discovering process.
The BChE mutants 1-5 have full length amino acid

lation time, along with root-mean-square deviation (RMSD)
in the enzyme-substrate complexes where FIG. 1A represents
the non-prereactive enzyme-substrate complexes; and FIG.
1B represents the prereactive enzyme-substrate complexes in
accordance with the present invention.
FIG. 2 shows the binding of structures of the simulated
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sequences, SEQ ID NOS: 2, 8, 14, 20, and 26, respectively,
which are encoded by nucleic acid sequences having SEQ ID

NOS: 1, 7, l3, l9, and 25, respectively. Table 1 summarizes
the catalytic ef?ciency against (—)-cocaine for the ?ve
mutants.

In addition to the full length BChE mutants, the respective

40

non-prereactive and prereactive complexes of wild-type

amino acid sequence can be truncated without substantially

BChE binding with two entomers of cocaine in which FIG.

affecting the respective catalytic activity. With all mutants,

2A depicts BChE (—)-cocaine non-prereactive complex; FIG.
2B depicts BChE (—)-cocaine prereactive complex, FIG. 2C
depicts BChE (+)-cocaine non-prereactive complex; and
FIG. 2D depicts BChE (+)-cocaine prereactive complex.

residues 1-67 and 443-574 can be removed without substan

FIG. 3A shows the (—)-cocaine rotation in the BChE active
site for the non-prereactive complex to the prereactive com
plex hindered by some residues at positions Y332, A328, and
F329 residues in the non-prereactive complexes which are

tially affecting the catalytic activity of the respective mutant
45

BChE. Further, with regard to mutant 1-4, amino acids 1-1 16
and 439-574 canbe omitted without substantially affecting its

respective catalytic activity. With regard to mutant 5, amino
acid residues 1-116 and 442-574 can be omitted without

substantially affecting its catalytic activity. Table 1 also pro
50

signi?cantly different from the corresponding positions in the
prereactive complex; and FIG. 3B shows the (+)-cocaine

vides a summary of amino acid SEQ ID NOS and correspond
ing nucleic acid SEQ ID NOS for the aforementioned trun
cated mutant BChE sequences.

TABLE 1

Partially
Truncated
Nucleic Acid

Amino
Amino
Mutant Acid
Number Substituting

1

2

A199S/
A328W/
Y332G
A199S/

Nucleic
Acid
Acid SEQ SEQ ID

SEQ ID NO

SEQ ID NO.

Sequence

SEQ ID NO.

Corresponding

for Amino

Catalytic

Corresponding
To Amino Acid

for Amino Acid
Residues

To Amino Acid
Residues

Acid
Residues

Ef?ciency
Against

ID NO.

NO.

Residues 68—442

68—442

117-43 8/441 *

117—43 8/441 *

(—)—cocaine

l

2

3

4

5

6

65-fold

7

8

9

10

ll

12

l48-fold

US 7,731,957 B1
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TABLE l-continued

Partially
Truncated
Nucleic Acid

Amino
Amino
Mutant Acid
Number Substituting

Nucleic
Acid
Acid SEQ SEQ ID

SEQ ID NO

SEQ ID NO.

Sequence

SEQ ID NO.

Corresponding

for Amino

Catalytic

Corresponding
To Amino Acid

for Amino Acid
Residues

To Amino Acid
Residues

Acid
Residues

Ef?ciency
Against

ID NO.

NO.

Residues 68—442

68—442

117—438/441 *

117-43 8/441*

(—)—cocaine

13

14

15

16

17

18

456-fold

19

20

21

22

22

24

1,003-fold

25

26

27

28

29

30

445-fold

A328W/
3

Y332G
A199S/

S287G/
A328W/
4

5

Y332G
A199S/
F227N
S287G/
A328W/
Y332G
A199S/
F227N
S287G/
A328W/
E441 D

(*Arnino acid residues 117—438 for mutants 1—4 and residues 117—441 for mutant 5.)
25

approach which ?rst models the potential BChE mutant inter
action with cocaine followed by generating the BChE mutant
if the predicted model indicates that the BChE variant should
have enhanced catalytic activity. The method includes gener

The BChE variant polypeptide, e.g., SEQ ID NOS: 2, 4, 6,
8, 10, l2, l4, l6, 18, 20, 22, 24, 26, 28, and 30 can be
formulated in a pharmaceutical composition along with a
suitable pharmaceutical carrier known to one skilled in the
art.

30

ating an initial structure of the transition state structure for the

The present BChE variant polypeptides can be used in
treating a cocaine-induced condition by administering to an

rate-determining step for the cocaine hydrolysis catalyzed by

individual, an effective amount of one of the BChE variant

dynamics simulation is performed on the transition state

a possible BChE mutant. A suf?ciently long time molecular
structure in water to have a stable molecular dynamics traj ec

polypeptides, i.e., SEQ ID NOS: 2, 4, 6, 8, 10, l2, l4, l6, 18,
20, 22, 24, 26, 28, and 30, to lower blood cocaine concentra
tion. The BChE variant polypeptide may be administered in
the form of a pharmaceutical composition in which the BChE
variant is included with a suitable pharmaceutical carrier.
Treatment of a cocaine induced condition using one of the
aforementioned BChE variant polypeptides can be done in
accordance with Zhan et al., page 2463.
The preferred dose for administration of a butyrylcho
linesterase or peptide composition in accordance with the
present invention is that amount which will be effective in

35
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hydrogen binding energies are estimated between the car
boxyl oxygen of the (—)-cocaine benzoyl ester and the oxya
nion hole of the possible BChE mutant. If the overall hydro

gen binding energy between the carboxyl oxygen of the (—)
cocaine benzoyl ester and the possible BChE mutant, in the
transition state, is stronger than the overall hydrogen binding
energy between the carboxyl oxygen of the (—)-cocaine ben

zoyl ester and the wild-type BChE, hybrid quantum mechani
cal/molecular mechanical (QM/MM) geometry optimization

lowering (—)-cocaine concentration in a patient’s blood
stream, and one would readily recognize that this amount will
vary greatly depending on the nature of cocaine consumed,
e.g., injected or inhaled, and the condition of a patient. An
“effective amount” of butyrylcholinesterase mutant or phar
maceutical agent to be used in accordance with the invention

tory. The molecular dynamics trajectory is analyzed and the

45

is intended to mean a nontoxic but suf?cient amount of the 50

agent, such that the desired prophylactic or therapeutic effect

is performed to re?ne the molecular dynamics-simulated
structure, the hydrogen binding energies are calculated and
the energy barrier is evaluated. The QM/MM calculations
make the computational predictions more reliable. Finally,
the BChE mutant is generated.
With regard to the molecular dynamics (MD) simulations
and quantum mechanical/molecular mechanical (QM/MM)
calculations, the ?rst chemical reaction step of (—)-cocaine

is produced. Thus, the exact amount of the enzyme or a

hydrolysis catalyzed by butyrylcholinesterase (BChE)

particular agent that is required will vary from subject to
subject, depending on the species, age, and general condition
of the subject, the severity of the condition being treated, the
particular carrier or adjuvant being used and its mode of

mutants and, when needed, other reaction steps are modeled

administration, and the like. Similarly, the dosing regimen

by protein expression. The afonnentioned ?ve mutants were

should also be adjusted to suit the individual to whom the
composition is administered and will once again vary with

identi?ed by computational analysis and generated by site

age, weight, metabolism, etc. of the individual. Accordingly,
the “effective amount” of any particular butyrylcholinest

and calculated using molecular dynamics simulations and
QM/MM calculations. Following this modeling, mutant
BChE’ s are created using site-directed mutagenesis followed

60

erase composition will vary based on the particular circum
stances, and an appropriate effective amount may be deter
mined in each case of application by one of ordinary skill in

of molecular modeling of a potential BChE mutant and MD
simulations and QM/MM calculations provide virtual screen

the art using only routine experimentation.
A unique method was used to determine potential BChE

mutants with projected increased catalytic activity for the
hydrolysis of cocaine. The method provides a unique

directed mutagenesis which have signi?cantly enhanced (—)
cocaine hydrolysis catalytic ef?ciency compared with wild
type BChE.
In the present method computational analysis in the form

65

ing of possible BChE mutants which have predicted enhanced
catalytic activity for (—)-cocaine. For example, the MD simu
lations and QM/MM calculations predict which mutation will
lead to a more stable transition state for the rate determining

US 7,731,957 B1
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step compared to the corresponding separated reagents, i.e.,

now quickly discover the BChE mutants with the signi?

free cocaine and free possible mutant BChE, where the more

cantly improved catalytic ef?ciency.

stable transition state leads to a lower energy barrier and

higher predicted catalytic ef?ciency. Only after the computa
tional analysis predicts enhanced catalytic ef?ciency, is site

In addition, to the differences mentioned above, the present
molecularmodeling of the BChE-cocaine binding also differs
from the prior modeling. The molecular modeling in the prior

directed mutagenesis conducted on wild-type BChE nucleic

art considered only one binding mode for each BChE-cocaine

system, without modeling the possible cocaine rotation in the

acid sequence to generate a mutant nucleic acid sequence
which is then used to express a mutant BChE protein. The

BChE active site after the binding. The present method con
siders two different binding modes for each BChE-cocaine
system and the structural transformation between them: non

mutant BChE protein is then used in catalytic assays to deter

mine the catalytic e?iciency against (—)-cocaine.

prereactive and prereactive BChE-cocaine complexes. The

The use of predictive, computational modeling of the
present method for identifying mutant BChE candidates and

present modeling provides more detailed information about
the BChE-cocaine binding and the subsequent structural

the resulting mutant BChE are novel and unexpected over

transformation.

prior conventional methods which will now be readily appar

The present method includes molecular dynamics simula
tions performed on the cocaine binding with both the wild
type BChE and the mutants whereas prior molecular dynam
ics simulations were only performed on the cocaine binding
with the wild-type BChE. As is shown below in the following

ent to one of ordinary skill in the art.

Using the present method, most discovered new mutants
include a speci?c mutation (Y332G) on residue #332. No
prior BChE mutant having the Y332G mutation had ever been
reported previously; only mutations Y332A and Y332M on
residue #332 had been tested previously by other researchers.
Prior to the present invention, there was no reason to expect

experiments, the computational prediction could be com
20

cocaine binding with the proposed mutants.

that a mutant includingY332G mutation should be better than
the corresponding mutant including Y332A mutation or
Y332M. Thus, the present mutants with a Y332G mutation

The present invention will now be discussed with regard to

the following non-limiting examples in the form of experi

which have enhanced catalytic activity represent a surprising
and unexpected result over prior BChE mutants.
A Y332G mutant (single mutation) was ?rst tested and
found that the Y332G mutant had a slightly low (or approxi

25

A328W/Y332A/Y419S.

A detailed computational study of cocaine binding with
30

below, the prior art did not reveal that any of the particular
combinations tested was expected to have an improved cata
lytic ef?ciency. The present method is based on the present
and the mutants.
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prior art is that high-performance computational modeling
and simulations of the detailed catalytic mechanism are per

cocaine binding with the enzyme (BChE) and was unable to
examine the detailed catalytic reaction process after the
BChE-cocaine binding. When molecular modeling was lim
ited to studying the BChE-cocaine binding, one could only
design a mutation to improve the BChE-cocaine binding

40

experimental tests were conducted on the catalytic activity of
these mutants for (—)-cocaine in order to verify the computa
tional predictions. All of the obtained results clearly demon
strate that molecular modeling and MD simulations of
cocaine binding with BChE mutants provide a reliable com

putational approach to the rational design of high-activity
mutants of BChE for the (—)-cocaine hydrolysis.
3D model of BChE. The initial coordinates of human
BChE used in the computational studies came from the X-ray
45

crystal structure deposited in the Protein Data Bank (pdb

code: 1POP). The missing residues (D2, D3, E255, D378,
D379, N455, L530, E531, and M532) in the X-ray crystal

without knowing whether the mutation will also speedup the
subsequent chemical reaction process or not.

To overcome the obstacles of prior challenges to using
computational techniques such as molecular docking and

consideration of the binding site suggests that these mutations
could be important for changing the (—) -cocaine rotation from

the non-prereactive complex to the prereactive complex. Wet

The primary improvement of the present method over the

formed, which includes modeling how cocaine binds with
BChE and the subsequent structural transformation and
chemical reaction process. The prior art only considered the

wild-type and mutant BChE’s starting from the available
X-ray crystal structure of wild-type BChE was performed.
The simulated mutants include A328W/Y332G, A328W/

Y332A, and A328W/Y332A/Y4I9S, as simple geometric

unique, extensive computational modeling and simulations of
the detailed catalytic mechanism for both the wild-type BChE

ments which are provided to enhance understanding of the
present invention but in no way limit its scope or applicability.
EXPERIMENT l: COMPUTATIONAL STUDY OF
COCAINE BINDING WITH WILD-TYPE AND MUTANT

BCHE’S FOR A328W/Y332G, A328W/Y332A, AND

mately equal) catalytic ef?ciency than the wild-type. So, only
an appropriate combination of different mutations on differ
ent residues could make the enzyme more active. As seen

pletely wrong without directly modeling and simulating
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structure were built using the automated homology modeling
tool Modeler disclosed by Sali, A.; Blundell, T. L. J. Mol.
Biol. 1990, 212 403, and Sali, A.; Blundell, T. L. J. Mol. Biol.

molecular dynamics simulation previously used by others

1993, 234, 779, herein incorporated by reference, and

which were based on an empirical force ?eld which cannot be

InsightII software (Accelrys, Inc.) with the default param

used to perform necessary reaction coordinate calculations
for the catalytic reaction process, a variety of state-of-the-art

eters.

computational techniques of homology modeling, molecular
docking, molecular dynamics, quantum mechanics (QM),

Molecular docking. Molecular docking was performed for
55

each non-prereactive protein-ligand binding complex. The
binding site was de?ned as a sphere with an approximately 15

and hybrid quantum mechanics/molecular mechanics (QM/

A radius around the active site residue $198. The amino acid
residues included in the binding site model are not contiguous
in the protein. Cocaine, considered as a ligand, was initially
positioned at 17 A in front of $198 of the binding site. Each

MM) were used for the rational design of the BChE mutants.
The combined use of these computational techniques, includ

ing QM and QM/MM, led to the study of the detailed reaction
coordinate of the BChE-catalyzed hydrolysis of cocaine
which, for the ?rst time, provided the detailed structures of all

BChE-cocaine binding complex was energy-minimized by
using the steepest descent algorithm ?rst until the maximum

transition states and intermediates existing in the reaction

energy derivative is smaller than 4 kcal/mol/A and then the

process and the corresponding energetics. These extensive
computational modeling and simulation studies provided for
the rational design of possible BChE mutants that not only

conjugated gradient algorithm until the maximum energy

can improve the BChE-cocaine binding, but also can speedup
the subsequent chemical reaction process. As a result, one can

65

derivative is smaller than 0.001 kcal/mol/A. The energy mini
mization was followed by a 300 ps molecular dynamics (MD)
simulation at T:298 K with a time step of 1 fs. During the
energy minimization and MD simulation, only cocaine and

US 7,731,957 B1
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the residues of BChE included in the binding site were
allowed to move, while the remaining part of the protein was
?xed. The energy-minimization and MD simulation for these

Molecular docking and MD simulation procedures
described above were performed to study cocaine binding
with wild-type BChE and three mutants, i.e., A328W/
Y332A, A328W/Y332A/Y419S, and A328W/Y332G. For
each protein system (wild-type or mutant BChE), the protein

processes were performed by using the Amber force ?eld

implemented in the Discoveri3/InsightII calculation engine,
disclosed by Cornell, W. D.; Cieplak, P.; Bayl), C. I.; Gould,
I. R.; Merz, Jr., K. M.; Ferguson, D. M.; Spellmeyer, D. C.;

binding with cocaine was considered in both the non-prere

active and prereactive enzyme-substrate complexes.

Fox, T.; Caldwell, J. W.; Kollman, P. A. J. Am. Chem. Soc.
1995, 117, 5179. The non-bonded cut-off method and the

Most of the MD simulations in water were performed on a

supercomputer, Superdome (shared-memory, with 4 nodes

dielectric constant were set up to group based (12 A cut-off

and 256 processors), at the Center for Computational Sci
ences, University of Kentucky. The other computations were

distance) and distance dependent, respectively (e:4r) in
accordance with Harvey, S. C. Proteins 1989, 5, 78-92, herein

carried out on SGI Fuel workstations and a 34-processors

incorporated by reference.

IBM x335 Linux cluster.

Molecular dynamic simulation in water. The initial coor

dinates used in the MD simulation of the non-prereactive

Experimental procedure. Site-directed mutagenesis of

complexes were determined by using the molecular docking
procedure described above, whereas the initial coordinates

human BChE cDNA was performed by the QuikChange
method of Braman, J .; Papworth, C.; Greener, A. Methods

used in the MD simulation of the prereactive complexes were

Mol. Biol. 1996, 57, 5731, herein incorporated by reference.

obtained from superimposing backbone of the X-ray crystal
structure to that of the previously disclosed simulated prere
active complex of Zhan et al between cocaine and a homology
model of wild-type BChE. Each BChE-cocaine binding com

Mutations were generated from wild-type human BChE in a
20

Lockridge, 0. Mol. Pharmacol. 1999, 55, 83, all herein incor

plex was neutralized by adding two chloride counterions and

porated by reference, kindly provided by Dr. Lockridge at

was solvated in a rectangular box of TIP3P water molecules

with a minimum solute-wall distance of 10 A. The general
procedure for carrying out the MD simulations in water is
similar to that used in our previously reported other compu
tational studies such as those in Zhan et al and (a) Zhan, C.-G.;

25

Chem. Soc. 1999, 121, 7279, (b) Koca, J.; Zhan, C.-G.; Rit

DNA polymerase, for replication ?delity. The PCR product
30

817, (c) Koca, J .; Zhan, C.-G.; Rittenhouse, R. C.; Ornstein,
R. L.J. Compul. Chem. 2003, 24, 368, herein all incorporated
by reference. These simulations were performed by using the

ney cell line 293T/ 17. Cells were grown to 80-90% con?u
35
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benzoic acid, the product of cocaine hydrolysis by BChE, we
used sensitive radiometric assays based on toluene extraction
of [3 H] cocaine labeled on its benzene ring were used in accor

were allowed to move during a 5000-step minimization with
45

energy-minimized, the system was slowly heated from T:10
K to T:300 K in 30 ps before the production MD simulation

for 500 ps. The full minimization and equilibration procedure

adjusted by isotropic position scaling. The particle mesh

50

for varying times. Reactions were stopped by adding 300 pl of
0.02 M HCl, which neutralized the liberated benzoic acid
while ensuring a positive charge on the residual cocaine.
[3H]benzoic acid was extracted by 1 ml of toluene and mea

sured by scintillation counting. Finally, the measured time
55

dependent radiometric data were ?tted to the kinetic equation
so that the catalytic ef?ciency (km/KM) was determined.
Depicted in FIG. 1 are plots of some important distances in

the MD-simulated (—)-cocaine binding with A328W/Y332G
60

Ewald (PME) method of Essmann, U.; Perera, L.; Berkowitz,
M. L.; Darden, T. A.; Lee, H., Pedersen; L. G. J. Chem. Phys.
1995, 98, 10089, herein incorporated by reference, was used
to treat long-range electrostatic interactions. A residue-based
cutoff of 10 A was applied to the noncovalent interactions.

dance with Masson, P.; Xie, W., Froment, M-T.; Levitsky, V.;
Fortier, P.-L.; Albaret, C.; Lockridge, 0. Biochim. Biophys.
Acta 1999, 1433, 281, herein incorporated by reference. In
brief, to initiate reactions, 100 nCi of [3H]cocaine was mixed
with 100 pl of culture medium. Reactions proceeded at 370 C.

was repeated for each mutant. The MD simulations were

reference) was applied to ?x all covalent bonds containing a
hydrogen atom, a time step of 2 fs was used, and the non-bond
pair list was updated every 10 steps. The pressure was

in Dulbecco’s modi?ed Eagle’s medium (DMEM)] was har
vested for a BChE activity assay. To measure cocaine and

ligand was frozen and the solvent molecules with counterions

1984, 81, 3684, herein incorporated by reference. The
SHAKE algorithm of Ryckaert, J. P.; Ciccotti, G.; Berendsen,
H. C. J. Comp. Phys. 1977, 23, 327 (herein incorporated by

ence in 6-well dishes and then transfected by Lipofectamine
2000 complexes of 4 pg plasmid DNA per each well. Cells
were incubated at 37° C. in a C02 incubator for 24 hours and
cells were moved to 60-mm culture vessel and cultured for
four more days. The culture medium [10% fetal bovine serum

optimized prior to the MD simulation. First, the protein

performed with a periodic boundary condition in the NPT
ensemble at T:300 K with Berendsen temperature coupling
and constant pressure (P:1 atm) with isotropic molecule
based scaling disclosed in Berendsen, H. C.; Postma, J. P. M.;
van Gunsteren, W. F.; DiNola, A.; Haak, J. R. J. Comp. Phys.

Escherichia coli, ampli?ed, and puri?ed. The DNA
sequences of the mutants were con?rmed by DNA sequenc

herein incorporated by reference. The solvated system was

the conjugate gradient algorithm and a 5 ps MD run at T:300
K. After full relaxation and the entire solvated system was

was treated with Dpn I endonuclease to digest the parental
DNA template. Modi?ed plasmid DNA was transformed into

ing. BChE mutants were expressed in human embryonic kid

Sander module of Amber7 program as taught by Case, D. A.;

Pearlman, D. A.; Caldwell, J. W.; Cheatham III, T. E.; Wang,
J.; Ross, W. S.; Simmerling, C. L.; Darden, T.A.; Merz, K. M.;
Stanton, R. V.; Cheng, A. L.; Vincent, J. J .; Crowley, M.; Tsui,
V.; Gohlke, H.; Radmer, R. J.; Duan,Y.; Pitera, J.; Massova, I.;
Seibel, G. L.; Singh, U. C.; Weiner, P. K.; Kollman, P. A.
(2002), AMBER 7, University of California, San Francisco,

University of Nebraska Medical Center. Using plasmid DNA
as template and primers with speci?c base-pair alterations,
mutations were made by polymerase chain reaction with Pfu

Norberto de Souza, O.; Rittenhouse, R.; Ornstein, R. L. J. Am.
tenhouse, R.; Ornstein, R. L. J. Am. Chem. Soc. 2001, 123,

pRc/CMV expression plasmid in accordance with Xie, W.;
Altamirano, C. V.; Bartels, C. F.; Speirs, R. J.; Cashman, J. R.;
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BChE versus the simulation time, along with root-mean
square deviation (RMSD) of the coordinates of backbone
atoms in the simulated structure from those in the X-ray
crystal structure. MD trajectories for other complexes were
similar to these two in FIG. 1, although the simulated average
distances are different. Summarized in Table 2 are the average

During the 500 ps production MD simulation, the coordinates

values of some important geometric parameters in the simu

of the simulated complex were saved every 1 ps.

lated complexes.
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TABLE 2
Average values of the geometric
parametersC

BChE—cocaine
binding“
wild-type
wild-type with

<D1>,mn

<D1> <D2> <D3> <D4>

RMSD“;
<T>

nonpre

re

5.60
7.64

.27
.69

.77
.88

.71
.30

.37
.83

67
61

1.14
1.15

.27
.13

7.11
7.06
5.18

.87
.96
.84

.30
.28
.64

.14
.52
.56

.01
.42
.97

51
60
64

1.58
1.20
2.66

1.65
.35
.62

(+)—cocainel7
A328W/Y332A
A328W/Y332G
A328W/Y332A/Y419S

“Refers to (—)—cocaine binding with wild—type human BChE or (—)—cocaine binding with a
mutant BChE, unless indicated otherwise.

bRefers to (+)—cocaine binding with wild—type human BChE.
C<D1>non and <D1> represent the average distances between the S198 O"7 atom and the carbo—

nyl carbon of the cocaine benzoyl ester in the simulated non—prereactive and prereactive
BChE—cocaine complexes, respectively. <D2>, <D3>, <D4> refer to the average values of the
simulated distances from the carbonyl oxygen of the cocaine benzoyl ester to the NH hydro—
gen atoms ofG116, G117, and A199 residues, respectively. <T> is the average value ofthe
dihedral angle formed by the S198 O"7 atom and the plane ofthe carboxylate group ofthe
cocaine benzoyl ester. See Scheme 2.
dThe root—mean—square deviation (RMSD) of the coordinates of backbone atoms in the simu—
lated structure from those in the X—ray crystal structure of BChE. “nonpre” and “pre” refer to

the non—prereactive and prereactive BChE—cocaine complexes, respectively.

(—)- and (+)-cocaine binding with wild-type BChE. FIG. 2 25 structure of Nicolet et al, one can see from FIG. 1 that the
RMSD values are all smaller than 1.3 A for the whole protein

shows the binding structures of the simulated non-prereactive

structures.

and prereactive complexes of wild-type BChE binding with

The MD simulations of the prereactive complexes reveal

the two enantiomers of cocaine. In the non-prereactive com

that wild-type BChE binding with (—)-cocaine is essentially

plexes with (—)- and (+)-cocaine, the methyl ester group of

the same as the binding with (+)-cocaine in the binding site,
except for the different positions of methyl ester group of the
substrates. The simulated average distances between the car
bonyl carbon of the benzoyl ester and S198 OY are 3.27 and

cocaine is positioned at the top of the H438 backbone, while
the cocaine benzoyl ester moiety is quasi-parallel to the
C40Y side chain of S198 with a dihedral angle 0 of —8° and

140°, respectively.

3.69 A for (—)-cocaine and (+)-cocaine, respectively. More
35

over, the (+)-cocaine is stabilized more effectively by the
formation of strong hydrogen bonds with the backbone NH of
residues G116, G117, and A199 as summarized above in

Table 2. The cocaine benzoyl ester moiety is positioned quasi
perpendicular to S198 C40Y with a dihedral angle 0 of ~67°
40

and ~61° for (—)- and (+)-cocaine, respectively.
A comparison was made between the currently simulated
structures of the BChE-cocaine binding with those simulated
previously by using a homology model of BChE and it was
noted that two major differences between the two sets of

ocn3
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structures. By using the X-ray crystal structure in accordance
with Nicolet et al, the acyl loop is positioned on the top of the
cocaine benzoyl ester moiety of the cocaine, whereas the acyl
loop is far from the cocaine benzoyl ester moiety in the
structure simulated starting from the homology model of
Zhan et al. The RMSD of the coordinates of backbone atoms

in the previously simulated prereactive BChE-(—)-cocaine

Scheme 2. Hydrolysis of (—)-cocaine and (+)-cocaine.
Here, 0 refers to the dihedral angle formed by S198 0V and
the plane of carboxylate group of the cocaine benzoyl ester as
shown in the structure diagram below.
The simulated internuclear distances between the carbonyl
oxygen of cocaine benzoyl ester group and the NH hydrogen
of G1 16, G117, and A199 are comparable for the two enan
tiomers. The simulated average distances between the carbo
nyl carbon of the benzoyl ester and S198 OY are 5.60 A and

5.18 A for (—)- and (+)-cocaine, respectively. Comparing the
simulated protein backbone structures to the X-ray crystal
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complex from those in the X-ray crystal structure of BChE is
~2.0 A for the entire protein and ~3 .0 A for the acyl loop. The
RMSD value became ~2.4 A for the entire protein and ~3.3 A
for the acyl loop, when the X-ray crystal structure was

replaced by the MD-simulated prereactive BChE-(—)-cocaine
complex starting from the X-ray crystal structure. Despite
60

these structural differences, the benzoyl ester group of the
ligand is still close to the key residues (S197, G116, and
G1 17) in the BChE binding site. Some signi?cant differences
are associated with the distances between the S198 OY atom

and the carbonyl carbon of the cocaine benzoyl ester in non
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prereactive complexes. The average values of this distance in
the non-prereactive complexes were ~9.5 and ~8.5 A for (—)
and (+)-cocaine, respectively, when a homology model was
used. Using the X-ray crystal structure to conduct the analy
sis, corresponding average values became ~5.6 and ~5.2 A,

US 7,731,957 B1
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respectively. Therefore, both (—)- and (+)-cocaine became
closer to the binding site when the homology model was

from the non-prereactive complex to the prereactive complex.
Further, (—)-cocaine binding with A328W/Y332G BChE is

replaced by the X-ray crystal structure. However, no signi?

very similar to the binding with A328W/Y332A BChE, but

cant changes of the binding in the prereactive complexes were
observed when the used homology model was replaced by the
X-ray crystal structure. The average values of the simulated

the position change of F329 residue caused by the (—)-cocaine
rotation was signi?cant only in A328W/Y332A BChE, thus
suggesting that the energy barrier for the (—)-cocaine rotation
in A328W/Y332G BChE should be slightly lower than that in
A328W/Y332A BChE.

distance between the S198 OY atom and the carbonyl carbon
of the cocaine benzoyl ester in the prereactive complexes are
always close to ~3 .5 A for both (—)- and (+)-cocaine no matter
whether the X-ray crystal structure or homology model of

Concerning (—)-cocaine binding with A328W/Y332A/
Y419S BChE,Y419 stays deep inside the protein and does not
directly contact with the cocaine molecule. The Y4 1 9S muta
tion was tested because it was initially expected that this
mutation would further increase the free space of the active
site pocket so that the (—)-cocaine rotation could be easier.
However, as seen in Table 2 above, the average distance

BChE was used as the starting structure. The similar compu

tational results obtained from the use of the X-ray crystal
structure and homology model of BChE provides evidence
that the fundamental structural and mechanistic insights
obtained from the previous computational studies of Zhan et
al are reliable, despites the previous simulations were per

between the carbonyl carbon of cocaine benzoyl ester and

formed by using the homology model when the X-ray crystal

S198 OY atom in the simulated prereactive complex was as

structure was not available.

long as 5.84 A. The average distances between the carbonyl
oxygen of the cocaine benzoyl ester and the NH hydrolysis

Further, the simulated structures of the non-prereactive
BChE-cocaine complexes were superimposed with the cor
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responding prereactive complexes. As shown in FIG. 3, the
(—)-cocaine rotation in the BChE active site from the non

prereactive complex to the prereactive complex is hindered
by some residues as the positions on332, A328, and F329
residues in the non-prereactive complex are signi?cantly dif
ferent from the corresponding positions in the prereactive
complex, whereas none of these residues hinders the (+)
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cocaine complexes.
(—)-cocaine binding with BChE mutants. Now that the
(—)-cocaine rotation from the non-prereactive complex to the
prereactive complex has been known to be the rate-determin
ing step of the BChE-catalyzed hydrolysis of (—)-cocaine as

to the internuclear distances, another interesting geometric
parameter is the dihedral angle, 6, formed by S198 0V and the
plane of the carboxylate group of the cocaine benzoyl ester.
As seen in Table 2, the 6 values in the prereactive complexes
of cocaine with wild-type BChE and all of the BChE mutants
other than A328W/Y332A/Y419S BChE all slightly deviate
from the ideal value of 90° for the nucleophilic attack of S 1 98
0V at the carbonyl carbon of cocaine. The 6 value in the

cocaine rotation in the BChE active site from the non-prere

active complex to the prereactive complex because these resi
dues stay in nearly the same positions in the two BChE-(+)

atoms of G116, G117, and A199 residues are between 4.56
and 6.97 A; no any hydrogen bond between them. In addition

prereactive complex of (—)-cocaine with A328W/Y332A/
Y419S BChE is 164°, which is considerably different from
the ideal value of 90°.

Catalytic activity. The aforementioned discussion provides
35

evidence that the energy barriers for the (—)-cocaine rotation
in A328W/Y332A and A328W/Y332G BChE’s from the

shown by Zhan et al, useful BChE mutants should be
designed to speci?cally accelerate the change from the non

non-prereactive complex to the prereactive complex, the rate

prereactive BChE-(—)-cocaine complex to the prereactive

cocaine, should be lower than that in the wild-type BChE.
Thus, the MD simulations predict that both A328W/Y332A
and A328W/Y332G BChE’s should have a higher catalytic

determining step for the BChE-catalyzed hydrolysis of (—)

complex. The question is whether MD simulation can be

performed to help design BChE mutants that have higher

40

catalytic activity for (—)-cocaine hydrolysis.

activity than the wild-type BChE for (—)-cocaine hydrolysis.

In the simulated non-prereactive complex, the average dis
tance between the carbonyl carbon of cocaine benzoyl ester
and S198 0V is 7.6 A forA328W/Y332A BChE and 7.1 A for

Further, the MD simulations also suggest that the energy
barrier for the (—)-cocaine rotation in A328W/Y332G BChE
should be slightly lower than that in A328W/Y332A BChE

A328W/Y332G BChE, as seen in Table 2 above. In the simu
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lated prereactive complex, the average values of this impor

the activity of A328W/Y332A BChE. In addition, the MD
simulations predict that A328W/Y332A/Y419S BChE

tant internuclear distance become 3.87 and 3.96 A for

A328W/Y332A and A328W/Y332G BChE’s, respectively.
Compared to the simulated wild-type BChE-(—)-cocaine pre
reactive complex, the average distances between the carbonyl

should have no catalytic activity, or have a considerably lower
50

carbon of the cocaine benzoyl ester and S198 0V in the pre

catalytic activity than the wild-type, for (—)-cocaine hydroly
sis because (—)-cocaine binds with the mutant BChE in a way
that is not suitable for the catalysis.

reactive complex of (—)-cocaine with A328W/Y332A and
A328W/Y332G BChE’s are all slightly longer, whereas the
average distances between the carbonyl oxygen of the
cocaine benzoyl ester and the NH of G1 16, G117, and A199
residues are all shorter. This provides evidence that (—)-co
caine more strongly bind with A328W/Y332A and A328W/

and, therefore, the catalytic activity ofA328W/Y332G BChE
for the (—)-cocaine hydrolysis should be slightly higher than

The catalytic ef?ciency (km/KM) of A328W/Y332A
BChE for (—)-cocaine hydrolysis was reported to be 8.56><
55

106M min—l, which is 9.39 times ofthe kcat/KMvalue (9.11><
105 M min—l) of the wild-type BChE. To examine these theo
retical predictions of the relative activity for A328W/Y332G
and A328W/Y332A/Y419S BChE’s, a A328W/Y332A,

Y332G BChE’s in the prereactive complexes. More impor
tantly, the (—)-cocaine rotation in the active site of A328W/

A328W/Y332G, andA328W/Y332A/Y419S BChE was pro

prereactive complex to the prereactive complex did not cause

duced through site-directed mutagenesis. To minimize the
possible systematic experimental errors of the kinetic data,

considerable changes of the positions of A332 (or G332),

kinetic studies were performed with all of three mutants

W328, and F329 residues as seen in FIG. 4, compared to the

under the same condition and compared the catalytic ef?
ciency ofthe A328W/Y332G and A328W/Y332A/Y419S to
that of the A328W/Y332A for (—)-cocaine hydrolysis at ben

Y332A and A328W/Y332G BChE’s from the non

(—)-cocaine rotation in the active site of wild-type BChE.
These results provide evidence that A328W/Y332A and
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A328W/Y332G BChE’s should be associated with lower

zoyl ester group. Based on the kinetic analysis of the mea

energy barriers than the wild-type for the (—)-cocaine rotation

sured time-dependent radiometric data, the ratio of the kcat/

US 7,731,957 B1
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KM value of A328W/Y332G BChE to the kcat/KM value of
A328W/Y332A BChE for the (—)-cocaine hydrolysis was

prereactive complex. Further, (—)-cocaine binding with

determined to be ~2.08, or A328W/Y332G BChE has a kcat/

sis. The radiometric data show no signi?cant catalytic activity
for A328W/Y332A/Y419S BChE. These experimental data

A328W/Y332A BChE, but the position change of F329 resi
due caused by the (—)-cocaine rotation was signi?cant only in
A328W/Y332A BChE, thus suggesting that the energy bar
rier for (—)-cocaine rotation in A328W/Y332G BChE should

are consistent with the theoretical predictions based on the
MD simulations.

be slightly lower than that in A328W/Y332A BChE. It has
also been demonstrated that (—)-cocaine binds with A328W/

Conclusion. Molecular modeling, molecular docking, and
molecular dynamics (MD) simulations were performed to

Y332A/Y419S BChE in a way that is not suitable for the

A328W/Y332G BChE is very similar to the binding with

KMvalue of ~1 .78><107M min“1 for the (—)-cocaine hydroly

catalysis.

study cocaine binding with human butyrylcholinesterase

Based on the computational results, both A328W/Y332A

(BChE) and its mutants, based on a recently reported X-ray
crystal structure of human BChE. The MD simulations of
cocaine binding with wild-type BChE led to average BChE
cocaine binding structures similar to those obtained recently

and A328W/Y332G BChE’s have catalytic activity for (—)
cocaine hydrolysis higher than that of wild-type BChE and
the activity of A328W/Y332G BChE should be slightly
higher than that of A328W/Y332A BChE, whereas A328W/
Y332A/Y419S BChE is expected to lose the catalytic activ
ity. The computational predictions are completely consistent
with the experimental kinetic data, providing evidence that
the used computational protocol, including molecular mod
eling, molecular docking, and MD simulations, is reliable in
prediction of the catalytic activity of BChE mutants for (—)

from the MD simulations based on a homology model of

BChE, despite the signi?cant difference found at the acyl
binding pocket. This con?rms the fundamental structural and
mechanistic insights obtained from the prior computational
studies of Zhan et al based on a homology model of BChE,

20

e.g., the rate-determining step for BChE-catalyzed hydrolysis
of biologically active (—)-cocaine is the (—)-cocaine rotation

cocaine hydrolysis.

in the BChE active site from the non-prereactive BChE-(—)

EXPERIMENT 2: MD SIMULATIONS AND QUAN
TUM MECHANICAL/MOLECULAR MECHANICAL

cocaine complex to the prereactive complex.
The MD simulations further reveal that the (—)-cocaine
rotation in the active site of wild-type BChE from the non

25

prereactive complex to the prereactive complex is hindered
by some residues such that the positions ofY332, A328, and
F329 residues in the non-prereactive complex are signi?
cantly different from those in the prereactive complex. Com

(QM/MM) CALCULATIONS RELATING TO A 199S/

A328W/Y332G MUTANT (MUTANT l) (SEQ ID NO: 1).
Generally speaking, for rational design of a mutant enzyme
with a higher catalytic activity for a given substrate, one needs
to design a mutation that can accelerate the rate-determining
30

step of the entire catalytic reaction process while the other

pared to (—)-cocaine binding with wild-type BChE, (—)-co

steps are not slowed down by the mutation. Reported com

caine more strongly bind with A328W/Y332A and A328W/
Y332G BChE’s in the prereactive complexes. More
importantly, the (—)-cocaine rotation in the active site of

putational modeling and experimental data indicated that the
formation of the prereactive BChE-(—)-cocaine complex (ES)
is the rate-determining step of (—)-cocaine hydrolysis cata

A328W/Y332A and A328W/Y332G BChE’s from the non

35

prereactive complex to the prereactive complex did not cause
considerable changes of the positions of A332 or G332,
W328, and F329 residues. These results provide evidence that

and Hamza, A.; Cho, H.; Tai, H.-H.; Zhan, C.-G. J. Phys.
Chem. B 2005, 109, 4776, herein incorporated by reference,
whereas the rate-determining step of the corresponding (+)

A328W/Y332A and A328W/Y332G BChE’s are associated

with lower energy barriers than wild-type BChE for the (—)
cocaine rotation from the non-prereactive complex to the

lyzed by wild-type BChE as disclosed by Sun et al, Zhan et al

40

cocaine hydrolysis is the chemical reaction process consist
ing of four individual reaction steps disclosed by Zhan et al
and shown in Scheme 3 and Scheme 4 below.

US 7,731,957 B1
25

26

Scheme 3. Schematic representation of BChE-catalyzed

were performed to model the protein environmental effects

hydrolysis of (—)-cocaine. Only QM-treated high-layer part

on the stabilization of the transition-state structure for BChE

of the reaction system in the QM/MM calculations are drawn.
Notation [H] refers to a non-hydrogen atom in the MM
treated low-layer part of the protein and the cut covalent bond
with this atom is saturated by a hydrogen atom. The dash lines
in the transition state structures represent the transition bonds.
This mechanistic understanding is consistent with the
experimental observation of Sun et al, that the catalytic rate

catalyzed hydrolysis of (—)-cocaine. The simulated and cal
culated results indicate that the transition-state structure can

be stabilized better by the protein environment in A199S/
A328W/Y332G mutant of BChE than that in the wild-type.
The computational modeling led to a prediction of the higher
catalytic ef?ciency for the Al99S/A328W/Y332G mutant

against (—)-cocaine. The prediction has been con?rmed by

constant of wild-type BChE against (+)-cocaine is pH-depen

wet experimental tests showing that the Al99S/A328W/
Y332G mutant has a signi?cantly improved catalytic ef?

dent, whereas that of the same enzyme against (—)-cocaine is
independent of the pH. The pH-dependence of the rate con
stant for (+)-cocaine hydrolysis is clearly associated with the
protonation of H438 residue in the catalytic triad (S198,
H438, and E325). For the ?rst and third steps of the reaction
process, when H438 is protonated, the catalytic triad cannot
function and, therefore, the enzyme becomes inactive. The
lower the pH of the reaction solution is, the higher the con
centration of the protonated H438 is, and the lower the con
centration of the active enzyme is. Hence, the rate constant
was found to decrease with decreasing the pH of the reaction

ciency against (—)-cocaine. All of the obtained results clearly
demonstrate that directly modeling the transition-state struc
ture provides a reliable computational approach to the ratio
nal design of a high-activity mutant of BChE against (—)
cocaine.
MD simulations. It should be stressed that a critical issue
exists with regard to any MD simulation on a transition state.

In principle, MD simulation using a classical force ?eld (mo
20

solution for the enzymatic hydrolysis of (+)-cocaine.
Based on the above mechanistic understanding, the efforts
for rational design of the BChE mutants reported in literature
have been focused on how to improve the ES formation

25

process. Indeed, several BChE mutants, including A328W,
A328W/Y332A, A328W/Y332G, and F227A/S287G/

always associated with a ?rst-order saddle point on the poten
tial energy surface. Hence, MD simulation using a classical
force ?eld cannot directly simulate a transition state without
any restraint on the geometry of the transition state. Never
theless, if one can technically remove the freedom of imagi
nary vibration in the transition state structure, then the num

A328W/Y332M, have been found to have a signi?cantly

higher catalytic ef?ciency (km/KM) against (—)-cocaine;
these mutants of BChE have an approximate 9 to 34-fold

lecular mechanics) can only simulate a stable structure cor
responding to a local minimum on the potential energy sur
face, whereas a transition state during a reaction process is

30

ber of vibrational freedoms (normal vibration modes) for a
nonlinear molecule will decrease from 3N—6. The transition

improved catalytic ef?ciency against (—)-cocaine. Experi

state structure is associated with a local minimum on the

mental observation also indicated that the catalytic rate con
stant of A328W/Y332A BChE is pH-dependent for both (—)

potential energy surface within a subspace of the reduced
vibrational freedoms, although it is associated with a ?rst
order saddle point on the potential energy surface with all of
the 3N—6 vibrational freedoms. Theoretically, the vibrational
freedom associated with the imaginary vibrational frequency

and (+)-cocaine. The pH-dependence reveals that for both

(—)- and (+)-cocaine, the rate-determining step of the
hydrolysis catalyzed by A328W/Y332A BChE should be

35

in the transition state structure can be removed by appropri

either the ?rst or the third step of the reaction process. Further,
if the third step were rate determining, then the catalytic

ately freezing the reaction coordinate. The reaction coordi
nate corresponding to the imaginary vibration of the transi

ef?ciency of the A328W/Y332A mutant against (—)-cocaine
should be as high as that of the same mutant against (+)
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also been observed that the A328W/Y332A mutant only has

a ~9-fold improved catalytic ef?ciency against (—)-cocaine,
whereas the A328W/Y332A mutation does not change the

tion state is generally characterized by a combination of some

key geometric parameters. These key geometric parameters

cocaine because the (—)- and (+)-cocaine hydrolyses share the
same third and fourth steps (see Scheme 3). However, it has
45

are bond lengths of the forming and breaking covalent bonds
for BChE-catalyzed hydrolysis of cocaine, as seen in Scheme
3. Thus, one just needs to maintain the bond lengths of the
forming and breaking covalent bonds during the MD simula

high catalytic activity against (+)-cocaine. This analysis of

tion on a transition state. Technically, one can maintain the

the experimental and computational data available in litera
ture clearly shows that the rate-determining step of (—)-co
caine hydrolysis catalyzed by the A328W/Y332A mutant

bond lengths of the forming and breaking covalent bonds by
simply ?xing all atoms within the reaction center, by using

should be the ?rst step of the chemical reaction process.

some constraints on the forming and breaking covalent
50

bonds, or by rede?ning the forming and breaking covalent

Further, recently reported computational modeling also sug

bonds. It should be pointed out that the only purpose of

gests that the formation of the prereactive BChE-(—)-cocaine
complex (ES) is hindered mainly by the bulky side chain of
Y332 residue in wild-type BChE, but the hindering can be

performing such type of MD simulation on a transition state

removed by the Y332A orY332G mutation. Therefore, start
ing from the A328W/Y332A or A328W/Y332G mutant, the

is to examine the dynamic change of the protein environment
55

truly rational design of further mutation(s) to improve the
catalytic ef?ciency of BChE against (—)-cocaine should aim
to decrease the energy barrier for the ?rst reaction step with

out signi?cantly affecting the ES formation and other chemi
cal reaction steps.
The following rational design of a high-activity mutant of
BChE against (—)-cocaine is based on detailed computational
modeling of the transition state for the rate-determining step
(i.e., the ?rst step of the chemical reaction process). Molecu

lar dynamics (MD) simulations and hybrid quantum
mechanical/molecular mechanical (QM/MM) calculations

surrounding the reaction center and the interaction between
the reaction center and the protein environment. For this
study, of interest is the simulated structures, as the total ener
gies calculated in this way are meaningless.
The initial BChE structures used in the MD simulations
were prepared based on the previous MD simulation in accor
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dance with Hamza et al on the prereactive ES complex for

wild-type BChE with (—)-cocaine in water by using Amber7
program package. The previous MD simulations on the pre

reactive BChE-(—)-cocaine complex (ES) started from the
65

X-ray crystal structure of Nicolet et al deposited in the Protein
Data Bank (pdb code: lPOP). The present MD simulation on
the transition state for the ?rst step (TSl) was performed in
such a way that bond lengths of the partially formed and

